What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab? Inflamm Bowel Dis. 2018 Apr 13;: Authors: Card T, Xu J, Liang H, Bhayat F Abstract Background: Progressive multifocal leukoencephalopathy is a serious condition linked to certain diseases and immunosuppressant therapies, including the α4 integrin antagonist natalizumab. No cases have been reported to date with vedolizumab, a selective antagonist of the α4β7 integrin expressed on gut-homing lymphocytes. This analysis aimed to describe the current and future expected occurrence of progressive multifocal…

Read More

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series.

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. Inflamm Bowel Dis. 2018 Apr 12;: Authors: Buer LCT, Høivik ML, Warren DJ, Medhus AW, Moum BA Abstract Background: Anti-tumor necrosis factor α (anti-TNF-α) is important in the treatment of inflammatory bowel disease, but some patients experience only a partial response. In these patients, a combination of anti-TNF-α and vedolizumab (VDZ) may act as a bridge until the full VDZ effect occurs. At present, clinical data on combination treatment with anti-TNF-α and VDZ are not available.…

Read More

Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease.

Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn’s Disease. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Waljee AK, Liu B, Sauder K, Zhu J, Govani SM, Stidham RW, Higgins PDR Abstract Background and Aims: Vedolizumab (VDZ) is effective for Crohn’s disease (CD) but costly and is slow to produce remission. Early knowledge of whether vedolizumab is likely to succeed is valuable for physicians, patients, and insurers. Methods: Phase 3 clinical trial data on VZD for CD were used to predict outcomes. Random forest modeling on the training cohort was used…

Read More

Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.

Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Ganguli A, Wang A Abstract Background: Extra-intestinal manifestations (EIMs) can impact morbidity in patients with inflammatory bowel diseases (IBD; Crohn’s disease [CD] and ulcerative colitis [UC]). This study compared incidence rates of EIMs in patients with moderate to severe IBD receiving gut-selective vedolizumab (VDZ) vs those receiving systemic anti-tumor necrosis factor (anti-TNF) therapies. Methods:…

Read More

Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.

Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 Mar 19;24(4):849-860 Authors: Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT Abstract Background: Vedolizumab is approved for moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). We present prospective, 1-year data of the real-world effectiveness and safety of vedolizumab in inflammatory bowel disease. Methods: Consecutive patients receiving vedolizumab for treatment of UC or CD with at least 14 weeks of follow-up, regardless…

Read More

Corrigendum: Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.

Corrigendum: Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. 2018 Mar 17;: Authors: Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D PMID: 29562246 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29562246?dopt=Abstract

Read More

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. Inflamm Bowel Dis. 2018 Mar 02;: Authors: Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochlar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV Abstract Background: Vedolizumab is now widely available for the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD). We sought to quantify the rates of postoperative complications with preoperative vedolizumab compared with anti-tumor…

Read More
<< Go Back